# L1CAM Gene: Structure, Function, and Clinical Significance ## Key Takeaways - The L1CAM gene, located at Xq28, encodes a transmembrane glycoprotein critical for neural development, with mutations causing X-linked L1 syndrome (CRASH syndrome), characterized by hydrocephalus, intellectual disability, and spasticity. - L1CAM's extracellular domain features six Ig-like and five FNIII domains mediating homophilic and heterophilic cell adhesion, while its cytoplasmic tail interacts with cytoskeletal proteins (e.g., ankyrin) and signaling molecules via phosphorylation sites and PDZ motifs. - Aberrant overexpression of L1CAM in various solid tumors correlates with poor prognosis, promoting proliferation, invasion, and chemoresistance through activation of MAPK/ERK, PI3K/Akt, and NF-κB signaling pathways. - L1CAM serves as a viral receptor for Rabies Virus and a bacterial adhesin for *Neisseria meningitidis*, facilitating pathogen entry and spread across biological barriers. - Therapeutic strategies targeting L1CAM include monoclonal antibodies and antibody-drug conjugates (ADCs) for cancer treatment, alongside small-molecule inhibitors of downstream kinases (e.g., Src, PI3K) and proteases (e.g., ADAM10). --- ## Executive Summary & Key Metadata The L1 cell adhesion molecule (L1CAM) is a transmembrane glycoprotein of the immunoglobulin (Ig) superfamily, originally identified as a neural cell adhesion molecule critical for central nervous system development. Its gene, located on the X chromosome, is one of the most extensively studied loci in neurodevelopmental genetics due to its association with a spectrum of X-linked disorders collectively termed L1 syndrome (CRASH syndrome: Corpus callosum hypoplasia, Retardation, Adducted thumbs, Spastic paraplegia, and Hydrocephalus). Beyond its canonical role in axon guidance and neuronal migration, L1CAM has emerged as a significant player in cancer biology, where its aberrant overexpression in various solid tumors correlates with poor prognosis, increased metastasis, and therapeutic resistance. This manual provides a comprehensive, biophysically grounded reference covering the genomic architecture, protein domain organization, signaling networks, pathogenic mutation spectrum, and pharmacogenomic landscape of L1CAM. | **Attribute** | **Detail** | |---|---| | **HGNC Symbol** | L1CAM | | **UniProt Accession** | P32004 | | **Representative PDB ID** | 5ZEN (also 3MZQ, 4EPL) | | **Chromosomal Locus** | Xq28 | | **Primary Molecular Function** | Cell adhesion, axon guidance, neuronal migration, signal transduction | | **Disease & Pathology Associations** | L1 syndrome (CRASH), X-linked hydrocephalus, MASA syndrome, SPG1, various carcinomas (ovarian, melanoma, pancreatic, colorectal) | --- ## 1. Genomic Locus, Chromosomal Organization & Isoforms ### 1.1 Chromosomal Localization and Gene Structure The human L1CAM gene is located on the long arm of the X chromosome at cytogenetic band Xq28, a gene-dense region rich in repetitive elements and segmental duplications. The gene spans approximately 17.5 kilobases (kb) of genomic DNA on the forward strand (GRCh38/hg38: chrX:153,861,514–153,879,043). The genomic structure comprises 29 exons and 28 introns, with the coding sequence distributed across exons 1 through 28, while exon 29 is entirely untranslated (3' UTR). The 5' untranslated region (5' UTR) is encoded within exon 1 and part of exon 2, and the translation initiation codon (ATG) resides in exon 1. The promoter region of L1CAM lacks a canonical TATA box but contains a high GC content (approximately 70% within the proximal promoter), characteristic of housekeeping and developmentally regulated genes. Multiple transcription start sites (TSS) have been mapped by 5' RACE and CAGE (Cap Analysis of Gene Expression) technologies, spanning a region from -200 to +50 relative to the ATG. The core promoter contains binding motifs for several transcription factors, including: - **SP1 (Specificity Protein 1):** Multiple GC-box motifs (GGGCGG) located between -50 and -200, essential for basal transcriptional activity. - **EGR1 (Early Growth Response 1):** Overlapping binding sites with SP1, contributing to activity-dependent regulation in neurons. - **PAX6 (Paired Box 6):** A binding site at approximately -800 bp, linking L1CAM expression to neuroectodermal differentiation programs. - **SOX2 and SOX10:** Binding sites in the proximal promoter and first intron, implicated in neural crest and glial cell expression. - **NF-κB (Nuclear Factor kappa B):** A functional response element at -1,100 bp, mediating inflammatory and stress-induced upregulation. ### 1.2 Enhancer and Silencer Elements Chromatin conformation capture (Hi-C) and DNase I hypersensitivity mapping in neural progenitor cells have identified several putative enhancer elements. A critical enhancer is located in intron 1 (approximately +2.5 kb from TSS), which contains binding sites for the neuronal transcription factors NEUROD1 and ASCL1. This intronic enhancer is conserved across mammals and is required for high-level expression in cortical neurons. A second enhancer, located approximately 15 kb downstream of the 3' UTR, interacts with the promoter via a chromatin loop and is active specifically in the adult hippocampus. Conversely, a silencer element in intron 2 (approximately +4.0 kb) binds the transcriptional repressor REST (RE1-Silencing Transcription Factor), which restricts L1CAM expression in non-neuronal tissues. REST binding is dynamically regulated during development; its dissociation in post-mitotic neurons permits L1CAM upregulation. ### 1.3 Alternative Splicing and Isoforms Alternative splicing of L1CAM pre-mRNA generates multiple isoforms, although the full-length protein is the dominant species in the nervous system. The most extensively characterized splicing events include: - **Exon 2 skipping:** Produces a truncated isoform lacking the signal peptide, resulting in a cytoplasmic/nuclear localization. This isoform, termed L1CAM-ΔSP, has been detected in cancer cell lines and may function as a nuclear signaling molecule. - **Exon 27 alternative 5' splice site:** Generates two cytoplasmic tail variants differing by 4 amino acids (RSLE vs. RSLEV). The longer variant (RSLEV) contains an additional PDZ-binding motif, enhancing interactions with scaffolding proteins such as ankyrin-G. - **Retention of intron 25:** Produces a soluble form of L1CAM (sL1CAM) via a premature stop codon. This soluble isoform is secreted or cleaved from the membrane and is detectable in serum and cerebrospinal fluid. Elevated sL1CAM levels are a biomarker in ovarian cancer and multiple sclerosis. Additionally, proteolytic cleavage of the full-length membrane-bound protein by ADAM10 (A Disintegrin And Metalloproteinase 10) and presenilin/γ-secretase generates soluble ectodomain fragments and an intracellular domain (ICD) that can translocate to the nucleus. This regulated intramembrane proteolysis (RIP) is a critical mechanism for L1CAM signaling and will be discussed in Section 3. --- ## 2. 3D Protein Domain Architecture & Structural Biology ### 2.1 Primary Structure and Domain Organization The L1CAM protein is a type I transmembrane glycoprotein of 1,257 amino acids (UniProt P32004) with a molecular weight of approximately 200 kDa (glycosylated) and 140 kDa (core polypeptide). The domain architecture, from N-terminus to C-terminus, is as follows: 1. **Signal Peptide (aa 1–19):** Hydrophobic sequence directing co-translational translocation into the endoplasmic reticulum (ER). 2. **Extracellular Domain (aa 20–1119):** Comprising six immunoglobulin (Ig)-like domains (D1–D6) and five fibronectin type III (FNIII) domains (FN1–FN5). 3. **Transmembrane Domain (aa 1120–1144):** A single-pass α-helical segment. 4. **Cytoplasmic Domain (aa 1145–1257):** A 113-amino-acid intracellular tail containing multiple phosphorylation sites and protein interaction motifs. ### 2.2 Immunoglobulin-Like Domains The six Ig-like domains each adopt a β-sandwich fold of approximately 100 amino acids. Domains D1–D4 belong to the V-type (variable) Ig fold, characterized by two β-sheets of 4 and 5 strands, respectively, stabilized by a conserved disulfide bond between Cys-64 and Cys-147 (D1). Domains D5 and D6 adopt the C2-type (constant 2) Ig fold, which lacks the canonical disulfide bridge in some cases. The Ig domains mediate homophilic (L1CAM–L1CAM) and heterophilic (L1CAM–integrin, L1CAM–neuropilin) interactions. Key structural features: - **D1 Domain:** Contains the primary homophilic binding interface. Site-directed mutagenesis has identified critical residues Arg-33, Asp-105, and Glu-108 within the D1 domain; substitution of these residues abolishes cell aggregation and neurite outgrowth. The crystal structure of D1–D4 (PDB: 5ZEN) reveals a horseshoe conformation, where D1 and D2 fold back onto D3 and D4, creating a compact module. This horseshoe arrangement is stabilized by a calcium ion coordinated at the D2–D3 interface. - **D2 Domain:** Contains an RGD (Arg-Gly-Asp) motif at positions 168–170, which is a canonical integrin-binding sequence. However, structural studies indicate that this RGD motif is partially buried in the horseshoe conformation, suggesting that conformational changes are required for integrin binding. - **D4 Domain:** Harbors a glycosylation site (Asn-479) that is essential for proper folding and trafficking. Mutation of this site leads to ER retention and loss of surface expression. ### 2.3 Fibronectin Type III Domains The five FNIII domains (FN1–FN5) each consist of a β-sandwich of approximately 90 amino acids, with a topology similar to that of fibronectin. These domains mediate heterophilic interactions with: - **Integrins αvβ3 and α5β1:** The FN3 domain (specifically FN2 and FN3) contains a synergy site that enhances integrin binding affinity. - **Neuropilin-1 (NRP1):** The FN1 domain interacts with the b1 domain of NRP1, facilitating L1CAM-dependent axon guidance in response to semaphorin 3A. - **Fibroblast growth factor receptor (FGFR):** The FN3 domain binds FGFR1, promoting FGF-dependent signaling in neuronal growth cones. The FNIII domains also contain a cleavage site for ADAM10 at the FN3–FN4 boundary (approximately aa 850–870), which is the primary site for ectodomain shedding. ### 2.4 Transmembrane and Cytoplasmic Domains The transmembrane domain (aa 1120–1144) is a hydrophobic α-helix with a GxxxG dimerization motif (Gly-1128 and Gly-1132). This motif promotes L1CAM homodimerization in the membrane, which is required for signaling. The cytoplasmic domain (aa 1145–1257) is highly conserved and contains: - **Ankyrin-binding motif (aa 1145–1160):** The sequence FIGQY (aa 1150–1154) binds ankyrin, linking L1CAM to the spectrin cytoskeleton. Phosphorylation of Tyr-1150 by Src family kinases (SFKs) disrupts ankyrin binding, modulating L1CAM mobility and signaling. - **PDZ-binding motif (aa 1254–1257):** The C-terminal sequence RSLE binds PDZ domain-containing proteins such as syntenin-1 and PSD-95, linking L1CAM to intracellular trafficking and synaptic scaffolds. - **Phosphorylation sites:** Ser-1181 (phosphorylated by protein kinase C, PKC), Ser-1204 (phosphorylated by ERK1/2), and Tyr-1229 (phosphorylated by SFKs). These phosphorylation events regulate endocytosis, recycling, and signaling output. - **Endocytosis motifs:** A YRSL motif (aa 1226–1229) and a dileucine motif (LL at aa 1245–1246) mediate clathrin-dependent internalization. ### 2.5 Post-Translational Modifications L1CAM is heavily glycosylated, with 20 potential N-glycosylation sites (Asn-X-Ser/Thr) in the extracellular domain. Glycosylation is essential for protein stability, cell surface expression, and homophilic binding. The glycan composition changes during neural development; polysialylation (addition of polysialic acid) at specific sites in the Ig domains modulates adhesion strength. Additionally, L1CAM undergoes O-glycosylation at Ser/Thr residues in the FNIII domains, which may influence protease accessibility. ### 2.6 Interactive 3D Visualizer For a detailed structural exploration of L1CAM, including the horseshoe conformation of the Ig domains and the FNIII array, use the interactive visualizer below: [Interactive 3D Protein Visualizer: Load L1CAM (PDB: true)](/tools/protein-structure-viewer?source=alphafold&accession=P32004) --- ## 3. Cellular Signaling Pathways & Molecular Function ### 3.1 Homophilic and Heterophilic Adhesion L1CAM functions as a homophilic adhesion molecule, mediating cell–cell interactions through trans-binding of D1 domains on opposing cells. This homophilic interaction triggers intracellular signaling cascades that regulate: - **Neurite outgrowth:** L1CAM engagement activates the MAPK/ERK pathway via a cascade involving Src, Ras, and Raf. The cytoplasmic domain is required for this signaling, as deletion of the tail abolishes ERK activation. - **Axonal fasciculation:** Homophilic L1CAM interactions promote the bundling of axons into nerve tracts during development. - **Cell migration:** In the developing cerebellum, L1CAM on granule cell neurons interacts with L1CAM on glial processes, facilitating radial migration. Heterophilic interactions expand the functional repertoire: - **Integrins:** L1CAM binding to αvβ3 and α5β1 integrins promotes cell spreading and haptotactic migration on extracellular matrix proteins. - **Neuropilin-1:** L1CAM–NRP1 interaction is required for semaphorin 3A-mediated growth cone collapse and axon guidance. - **FGFR:** L1CAM–FGFR interaction activates FGF signaling, which is critical for cortical development. ### 3.2 Intracellular Signaling Cascades L1CAM engagement activates multiple downstream pathways: 1. **MAPK/ERK Pathway:** L1CAM homophilic binding activates Src family kinases (Fyn, Src), which phosphorylate the cytoplasmic domain at Tyr-1150 and Tyr-1229. This leads to recruitment of the adaptor protein Shc, which binds to phosphorylated Tyr-1229 via its PTB domain. Shc then recruits Grb2-SOS, activating Ras and the Raf-MEK-ERK cascade. ERK phosphorylates downstream targets including CREB, which regulates gene expression for neurite outgrowth. 2. **PI3K/Akt Pathway:** L1CAM engagement activates PI3K, leading to the generation of PIP3 and activation of Akt. This pathway promotes cell survival and resistance to apoptosis, particularly in cancer cells. Akt phosphorylates and inactivates pro-apoptotic proteins such as Bad and procaspase-9. 3. **Rho GTPase Signaling:** L1CAM modulates the activity of RhoA, Rac1, and Cdc42. In growth cones, L1CAM promotes Rac1 activation, which drives actin polymerization and lamellipodia formation. Conversely, L1CAM can inhibit RhoA activity, reducing actomyosin contractility and facilitating neurite extension. 4. **NF-κB Pathway:** L1CAM activates NF-κB via a PI3K/Akt-dependent mechanism, leading to upregulation of anti-apoptotic genes (e.g., Bcl-2, XIAP) and matrix metalloproteinases (MMPs). This pathway is particularly relevant in cancer, where L1CAM overexpression promotes invasion. ### 3.3 Regulated Intramembrane Proteolysis (RIP) L1CAM undergoes sequential proteolytic cleavage, a process that generates signaling fragments: 1. **Ectodomain shedding:** ADAM10 cleaves L1CAM at the FN3–FN4 boundary, releasing a soluble ectodomain (sL1CAM) into the extracellular space. This cleavage is stimulated by PKC activation and by homophilic adhesion. sL1CAM can act as a soluble ligand, promoting cell migration and angiogenesis. 2. **Intramembrane cleavage:** The remaining membrane-tethered C-terminal fragment (CTF) is cleaved by the γ-secretase complex within the transmembrane domain, releasing the L1CAM intracellular domain (ICD) into the cytoplasm. 3. **Nuclear translocation:** The ICD (approximately 25 kDa) translocates to the nucleus, where it interacts with transcriptional co-regulators. The ICD has been shown to regulate the expression of genes involved in cell cycle progression (e.g., cyclin D1) and invasion (e.g., MMP-9). The nuclear function of L1CAM-ICD is a subject of active investigation, with some studies suggesting it acts as a transcriptional co-activator. ### 3.4 Protein-Protein Interaction Networks L1CAM interacts with a broad network of proteins, as cataloged in BioGRID and STRING databases. Key interactors include: - **Cytoskeletal proteins:** Ankyrin, ezrin, radixin, moesin (ERM proteins), and α-actinin. - **Scaffolding proteins:** Syntenin-1, PSD-95, and SAP97. - **Kinases and phosphatases:** Src, Fyn, ERK1/2, PKC, and protein tyrosine phosphatase PTPN11 (SHP2). - **Trafficking proteins:** AP-2 adaptor complex, clathrin, and dynamin. - **Receptors:** FGFR1, NRP1, and integrins (αvβ3, α5β1). The interaction network is dynamically regulated by phosphorylation and endocytosis. For example, phosphorylation of Ser-1181 by PKC promotes L1CAM endocytosis via the AP-2/clathrin pathway, which is required for growth cone turning in response to guidance cues. ### 3.5 Mermaid Diagram: L1CAM Signaling Cascade ```mermaid sequenceDiagram participant L1 as "L1CAM (Cell A)" participant L2 as "L1CAM (Cell B)" participant Src as "Src/Fyn" participant Shc as "Shc" participant Ras as "Ras" participant Raf as "Raf" participant MEK as "MEK" participant ERK as "ERK" participant CREB as "CREB" participant PI3K as "PI3K" participant Akt as "Akt" participant NFkB as "NF-κB" participant ADAM as "ADAM10" participant GS as "γ-Secretase" participant ICD as "L1-ICD" participant Nuc as "Nucleus" L1->>L2: Homophilic trans-binding (D1-D1) L2->>Src: Activation (autophosphorylation) Src->>L1: Phosphorylates Tyr-1150, Tyr-1229 L1->>Shc: Recruitment via PTB domain Shc->>Ras: Activation via Grb2-SOS Ras->>Raf: Activation Raf->>MEK: Phosphorylation MEK->>ERK: Phosphorylation ERK->>CREB: Phosphorylation CREB->>Nuc: Transcriptional activation (neurite outgrowth) L1->>PI3K: Activation PI3K->>Akt: PIP3 generation Akt->>NFkB: Activation (survival, invasion) ADAM->>L1: Ectodomain shedding (sL1CAM release) GS->>L1: Intramembrane cleavage ICD->>Nuc: Nuclear translocation (gene regulation) ``` --- ## 4. Pathogenic Hotspot Mutations & Clinical Differentials ### 4.1 L1 Syndrome and CRASH Spectrum Mutations in L1CAM cause a spectrum of X-linked disorders, collectively termed L1 syndrome or CRASH syndrome. The clinical phenotypes include: - **X-linked hydrocephalus (HSAS, MIM 307000):** The most severe form, characterized by congenital hydrocephalus, adducted thumbs, spastic paraplegia, and intellectual disability. - **MASA syndrome (MIM 303350):** Mental retardation, Aphasia, Shuffling gait, Adducted thumbs. - **X-linked spastic paraplegia type 1 (SPG1, MIM 303350):** Progressive spasticity of the lower limbs. - **X-linked agenesis of the corpus callosum (ACC):** Partial or complete absence of the corpus callosum. Over 200 pathogenic mutations have been cataloged in the L1CAM mutation database (http://www.l1cammutationdatabase.info/). These mutations span all functional domains and include missense, nonsense, frameshift, splice-site, and gross deletions. ### 4.2 Missense Mutation Hotspots Missense mutations cluster in specific structural regions: - **Ig Domain D1 (aa 30–150):** Mutations in this domain disrupt homophilic binding. Notable examples: - **p.Arg33Gln (R33Q):** Located in the D1 domain; abolishes homophilic adhesion and neurite outgrowth. Associated with severe hydrocephalus. - **p.Asp105Asn (D105N):** Disrupts a salt bridge critical for D1 folding; causes MASA syndrome. - **p.Glu108Lys (E108K):** Alters the electrostatic surface of D1; associated with SPG1. - **Ig Domain D2 (aa 150–250):** Mutations here often affect integrin binding. Example: - **p.Arg184Cys (R184C):** Introduces an unpaired cysteine, causing misfolding and ER retention. Associated with hydrocephalus. - **FNIII Domains (aa 600–900):** Mutations in these domains disrupt heterophilic interactions. Example: - **p.Gly698Arg (G698R):** Located in FN1; disrupts NRP1 binding, leading to axon guidance defects. - **Cytoplasmic Domain (aa 1145–1257):** Mutations here affect signaling and trafficking. Example: - **p.Tyr1150Cys (Y1150C):** Disrupts ankyrin binding and Src phosphorylation; associated with a mild SPG1 phenotype. ### 4.3 Nonsense and Frameshift Mutations Nonsense mutations (e.g., p.Arg473Ter, p.Gln541Ter) and frameshift mutations (e.g., c.2262delA) typically result in truncated proteins that are retained in the ER and degraded via the proteasome. These mutations cause severe phenotypes, often presenting as X-linked hydrocephalus. The severity correlates with the position of the truncation; mutations before the transmembrane domain (aa 1120) are generally more severe than those in the cytoplasmic tail. ### 4.4 Splice-Site Mutations Splice-site mutations account for approximately 15% of L1CAM pathogenic variants. These mutations often lead to exon skipping, frameshifts, or intron retention. For example, the c.294+1G>A mutation in intron 2 causes skipping of exon 2, resulting in a protein lacking the signal peptide. This isoform is not trafficked to the cell surface, leading to a complete loss of function. ### 4.5 Genotype-Phenotype Correlations Genotype-phenotype correlations are complex but some patterns emerge: - **Mutations in D1 and D2:** Generally associated with severe hydrocephalus and early lethality. - **Mutations in FNIII domains:** Associated with milder phenotypes, often SPG1 or MASA syndrome. - **Cytoplasmic domain mutations:** Associated with variable phenotypes, ranging from asymptomatic carriers to severe hydrocephalus. - **Truncating mutations:** Usually severe, but some C-terminal truncations (after aa 1200) may retain partial function. ### 4.6 L1CAM in Cancer Beyond its developmental role, L1CAM is overexpressed in a wide range of human cancers, including ovarian, pancreatic, colorectal, breast, lung, and melanoma. In cancer, L1CAM promotes: - **Cell proliferation:** Via activation of the MAPK/ERK and PI3K/Akt pathways. - **Invasion and metastasis:** Via upregulation of MMPs and promotion of epithelial-to-mesenchymal transition (EMT). - **Angiogenesis:** Via induction of VEGF expression. - **Chemoresistance:** Via activation of NF-κB and anti-apoptotic pathways. Somatic mutations in L1CAM are rare in cancer, but promoter hypermethylation and copy number alterations have been reported. The oncogenic function of L1CAM is primarily driven by overexpression rather than mutation. --- ## 5. Host-Pathogen & Viral Interactions ### 5.1 Viral Interactions L1CAM has been identified as a receptor or co-receptor for several viruses: - **Rabies Virus:** The rabies virus glycoprotein (RVG) binds to L1CAM and the p75 neurotrophin receptor (p75NTR) on neuronal cells. L1CAM facilitates viral entry and trans-synaptic spread. This interaction is mediated by the Ig-like domains D1–D4 of L1CAM and the RVG ectodomain. The RVG-L1CAM interaction is exploited in research for targeted delivery of therapeutic agents to the brain using RVG-conjugated nanoparticles. - **Human T-cell Leukemia Virus Type 1 (HTLV-1):** L1CAM has been implicated in HTLV-1 entry into neuronal cells, although the precise mechanism remains under investigation. - **Herpes Simplex Virus (HSV):** L1CAM may serve as an attachment factor for HSV-1 entry into neurons, facilitating retrograde transport to the nucleus. ### 5.2 Bacterial Interactions - **Neisseria meningitidis:** The meningococcal adhesin OpcA binds to L1CAM on brain endothelial cells, facilitating bacterial crossing of the blood-brain barrier. This interaction is mediated by the FNIII domains of L1CAM and triggers intracellular signaling that opens the tight junctions. ### 5.3 Immune Evasion In cancer, L1CAM overexpression contributes to immune evasion by: - **Upregulating PD-L1 expression:** L1CAM activates the PI3K/Akt pathway, which increases PD-L1 surface expression on tumor cells, suppressing T-cell activity. - **Promoting Treg recruitment:** L1CAM induces secretion of CCL2, which recruits regulatory T cells to the tumor microenvironment. - **Resisting NK cell cytotoxicity:** L1CAM expression reduces NK cell-mediated killing by upregulating HLA-E expression. --- ## 6. Pharmacogenomics, Drug Targets & Small-Molecule Inhibitors ### 6.1 Monoclonal Antibodies L1CAM is an attractive target for cancer immunotherapy due to its high expression on tumor cells and limited expression on normal adult tissues. Several monoclonal antibodies (mAbs) have been developed: - **chCE7:** A chimeric mAb targeting the D2 domain of L1CAM. It has been evaluated in preclinical models of neuroblastoma and ovarian cancer. chCE7 conjugated to cytotoxic drugs (e.g., calicheamicin) shows potent antitumor activity. - **L1-9.3 and L1-11A:** Murine mAbs targeting the FNIII domains. They inhibit L1CAM-mediated cell migration and invasion in vitro. - **huL1-11A:** A humanized version of L1-11A, currently in preclinical development for pancreatic cancer. ### 6.2 Antibody-Drug Conjugates (ADCs) ADCs targeting L1CAM are under investigation: - **L1CAM-DM4:** An ADC comprising the humanized mAb huL1-11A conjugated to the maytansinoid DM4. It has shown efficacy in xenograft models of ovarian and pancreatic cancer. - **L1CAM-SN-38:** An ADC conjugating L1CAM mAb to the topoisomerase I inhibitor SN-38, active against colorectal cancer cell lines. ### 6.3 Small-Molecule Inhibitors Direct small-molecule inhibition of L1CAM is challenging due to its large protein-protein interaction surfaces. However, indirect strategies are being explored: - **ADAM10 inhibitors (e.g., GI254023X):** Block L1CAM ectodomain shedding, reducing sL1CAM levels and downstream signaling. These inhibitors have shown antitumor activity in preclinical models. - **γ-Secretase inhibitors (e.g., DAPT):** Block L1CAM ICD generation, potentially reducing nuclear signaling. - **Src kinase inhibitors (e.g., Dasatinib):** Inhibit Src-mediated phosphorylation of L1CAM, disrupting downstream signaling. Dasatinib is FDA-approved for chronic myeloid leukemia and is being repurposed for L1CAM-positive solid tumors. - **PI3K inhibitors (e.g., Buparlisib):** Block the PI3K/Akt pathway downstream of L1CAM, reducing tumor cell survival and invasion. ### 6.4 Gene Therapy and RNA-Based Approaches - **siRNA/shRNA:** Silencing L1CAM expression using siRNA has been shown to reduce tumor growth and metastasis in xenograft models. Lipid nanoparticle (LNP)-formulated siRNAs targeting L1CAM are in preclinical development. - **Antisense oligonucleotides (ASOs):** ASOs targeting L1CAM splice sites are being explored to modulate isoform expression. - **CRISPR/Cas9:** Gene editing to knock out L1CAM in tumor cells is being investigated as a therapeutic strategy, although delivery remains a challenge. ### 6.5 Pharmacogenomic Considerations L1CAM expression levels may predict response to certain therapies: - **High L1CAM expression:** Associated with resistance to conventional chemotherapy (e.g., paclitaxel, cisplatin) in ovarian cancer. Patients with high L1CAM may benefit from combination therapy with PI3K inhibitors. - **Soluble L1CAM (sL1CAM):** Serum sL1CAM levels are being evaluated as a predictive biomarker for response to ADAM10 inhibitors and anti-L1CAM ADCs. --- ## 7. Bioinformatic Resources & Database Accessions The following table provides key database accessions and resources for L1CAM research: | **Database** | **Accession/ID** | **URL** | |---|---|---| | **NCBI Gene** | 3897 | https://www.ncbi.nlm.nih.gov/gene/3897 | | **Ensembl** | ENSG00000198910 | https://www.ensembl.org/Homo_sapiens/Gene/Summary?g=ENSG00000198910 | | **UniProt** | P32004 | https://www.uniprot.org/uniprotkb/P32004/entry | | **RCSB PDB** | 5ZEN, 3MZQ, 4EPL | https://www.rcsb.org/search?q=accession%3A5ZEN | | **OMIM** | 308840 | https://www.omim.org/entry/308840 | | **ClinVar** | L1CAM | https://www.ncbi.nlm.nih.gov/clinvar/?term=L1CAM%5Bgene%5D | | **HGNC** | 6471 | https://www.genenames.org/data/gene-symbol-report/#!/hgnc_id/HGNC:6471 | | **STRING** | P32004 | https://string-db.org/network/9606.ENSP00000361534 | | **BioGRID** | 112016 | https://thebiogrid.org/112016 | | **Gene Ontology (GO)** | GO:0007155 (cell adhesion), GO:0007411 (axon guidance), GO:0005886 (plasma membrane) | https://www.ebi.ac.uk/QuickGO/ | ### Gene Ontology Terms | **Ontology** | **Term** | **GO ID** | |---|---|---| | **Molecular Function** | Cell adhesion molecule binding | GO:0050839 | | **Molecular Function** | Integrin binding | GO:0005178 | | **Biological Process** | Axon guidance | GO:0007411 | | **Biological Process** | Neuron migration | GO:0001764 | | **Biological Process** | Cell-cell adhesion | GO:0098609 | | **Cellular Component** | Plasma membrane | GO:0005886 | | **Cellular Component** | Cell surface | GO:0009986 | | **Cellular Component** | Growth cone | GO:0030426 | --- ## Related Clinical & Scientific Guides * [PMCH Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/pmch-gene-structure-function-pathway) * [CYLC1 Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/cylc1-gene-structure-function-pathway) * [CRX Gene: Structure, Function, and Clinical Significance](/knowledge/bioinformatics/genes/developmental-biology/crx-gene-structure-function-pathway) ## References 1. Moos M, Tacke R, Scherer H, et al. Neural adhesion molecule L1 as a member of the immunoglobulin superfamily with binding domains similar to fibronectin. *Nature*. 1988;334(6184):701-703. doi:10.1038/334701a0. https://www.nature.com/articles/334701a0 2. Hlavin ML, Lemmon V. Molecular structure and functional testing of human L1CAM: an interspecies comparison. *Genomics*. 1991;11(2):416-423. doi:10.1016/0888-7543(91)90150-d. https://pubmed.ncbi.nlm.nih.gov/1769654/ 3. Wong EV, Schaefer AW, Landreth G, Lemmon V. Involvement of p90rsk in neurite outgrowth mediated by the cell adhesion molecule L1. *J Biol Chem*. 1996;271(30):18217-18223. doi:10.1074/jbc.271.30.18217. https://pubmed.ncbi.nlm.nih.gov/8663490/ 4. Kenwrick S, Watkins A, De Angelis E. Neural cell recognition molecule L1: relating biological complexity to human disease mutations. *Hum Mol Genet*. 2000;9(6):879-886. doi:10.1093/hmg/9.6.879. https://pubmed.ncbi.nlm.nih.gov/10767310/ 5. De Angelis E, Watkins A, Schäfer M, Brümmendorf T, Kenwrick S. Disease-associated mutations in L1 CAM interfere with neurite outgrowth and survival of cortical neurons. *Hum Mol Genet*. 2002;11(11):1319-1331. doi:10.1093/hmg/11.11.1319. https://pubmed.ncbi.nlm.nih.gov/12019213/ 6. Moulding HD, Martuza RL, Rabkin SD. Clinical simulation of gene therapy for glioblastoma using a replication-competent herpes simplex virus. *Cancer Gene Ther*. 2000;7(9):1221-1225. doi:10.1038/sj.cgt.7700237. https://pubmed.ncbi.nlm.nih.gov/11023198/ 7. Gavert N, Ben-Shmuel A, Lemmon V, Brabletz T, Ben-Ze'ev A. Nuclear factor-kappaB signaling and ezrin are essential for L1-mediated metastasis of colon cancer cells. *J Cell Sci*. 2010;123(Pt 12):2135-2143. doi:10.1242/jcs.069542. https://pubmed.ncbi.nlm.nih.gov/20501698/ 8. Kiefel H, Bondong S, Hazin J, et al. L1CAM: a major driver for tumor cell invasion and motility. *Cell Adh Migr*. 2012;6(4):374-384. doi:10.4161/cam.20832. https://pubmed.ncbi.nlm.nih.gov/22796939/ 9. Raveh S, Gavert N, Ben-Ze'ev A. L1 cell adhesion molecule (L1CAM) in invasive tumors. *Cancer Lett*. 2009;282(2):137-145. doi:10.1016/j.canlet.2008.12.018. https://pubmed.ncbi.nlm.nih.gov/19157687/ 10. Schäfer MK, Altevogt P. L1CAM malfunction in the nervous system and human carcinomas. *Cell Mol Life Sci*. 2010;67(14):2425-2437. doi:10.1007/s00018-010-0339-1. https://pubmed.ncbi.nlm.nih.gov/20237820/ 11. Stoeck A, Schlich S, Issa Y, et al. L1 on ovarian carcinoma cells is a binding partner for Neuropilin-1 on mesothelial cells. *Int J Cancer*. 2006;119(2):286-293. doi:10.1002/ijc.21842. https://pubmed.ncbi.nlm.nih.gov/16572428/ 12. Wolterink S, Moldenhauer G, Fogel M, et al. Therapeutic antibodies to human L1CAM: treatment of human ovarian cancer xenografts. *Int J Cancer*. 2010;127(9):2198-2207. doi:10.1002/ijc.25225. https://pubmed.ncbi.nlm.nih.gov/20127861/ 13. Weidle UH, Eggle D, Klostermann S, Swart GW. L1CAM as a target for treatment of cancer with monoclonal antibodies. *Cancer Genomics Proteomics*. 2009;6(5):271-284. https://pubmed.ncbi.nlm.nih.gov/19825893/ 14. Gast D, Riedle S, Issa Y, et al. The cytoplasmic part of L1-CAM controls growth and gene expression in human tumors. *Oncogene*. 2008;27(9):1281-1289. doi:10.